aTyr Pharma, Inc.(US:ATYR) Prnewswire·2025-11-17 13:45Core Viewpoint - aTyr Pharma, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the efficacy of its drug Efzofitimod, which failed to meet its primary endpoint in a clinical study, leading to a significant drop in stock price [1]. Summary by Sections Allegations - The complaint alleges that aTyr Pharma provided overly positive statements about Efzofitimod while concealing material adverse facts about its efficacy, particularly its ability to allow patients to taper steroid usage completely [1]. - The truth about the drug's performance was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, specifically regarding the change from baseline in mean daily OSC dose at week 48 [1]. Stock Price Impact - Following the announcement of the disappointing study results, aTyr's stock price plummeted from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, marking a decline of 83.2% in just one day [1]. Class Action Details - Shareholders who purchased shares during the class period from November 7, 2024, to September 12, 2025, are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for December 8, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [2].